![David de Graaf](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David de Graaf
Directeur Général chez
Reverb Therapeutics
Profil
Dr. David de Graaf is a Chief Executive Officer at Reverb Therapeutics, inc.
and an Independent Director at Mediar Therapeutics, Inc. He is on the Board of Directors at Mediar Therapeutics, Inc. Dr. de Graaf was previously employed as a Chief Executive Officer by Abcuro, Inc., a President & Chief Executive Officer by Comet Therapeutics, Inc., a Chairman & President by Selventa, Inc., and a President, Chief Executive Officer & Director by Syntimmune, Inc. He received his doctorate degree from the University of Illinois.
Postes actifs de David de Graaf
| Sociétés | Poste | Début |
|---|---|---|
Reverb Therapeutics
 Reverb Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a preclinical-stage biotechnology and biopharmaceutical company that develops immunotherapies for cancer and autoimmune diseases | Directeur Général | 01/01/2022 |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Directeur/Membre du Conseil | - |
Anciens postes connus de David de Graaf
| Sociétés | Poste | Fin |
|---|---|---|
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders | Directeur Général | 01/07/2020 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Directeur Général | 03/01/2018 |
Selventa, Inc.
 Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new approaches for the understanding and treatment of diseases | Président | - |
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Directeur Général | - |
Formation de David de Graaf
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
17
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Health Technology |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selventa, Inc.
Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new approaches for the understanding and treatment of diseases | Commercial Services |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Commercial Services |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Health Technology |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders | Health Technology |
Reverb Therapeutics
Reverb Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a preclinical-stage biotechnology and biopharmaceutical company that develops immunotherapies for cancer and autoimmune diseases | Commercial Services |
